There are no significant differences in outcomes post-AMI in patients with systemic lupus erythematosus vs the general population.

REPEAT kidney biopsies may play an essential role in managing lupus nephritis, particularly for patients whose disease ...

Immune cells called monocytes produce a key inflammatory protein called interleukin-1 beta (IL-1β) through an unconventional ...

Panelists discuss the challenges patients face in accessing lupus nephritis treatment and the resources available to support ...

The community came together to celebrate and honor Javari Fannin, an 18-year-old lupus survivor, who will be recognized as ...

Thousands of passionate people with lupus and those who care about the cause will join together Saturday, October 19 at the ...

Kezar’s decision to terminate the PALIZADE IIb trial comes after it was placed on a clinical hold due to four patient deaths.

In a first, the guidelines link poor pregnancy outcomes to stroke and call on doctors to exercise greater vigilance.

Earlier this month, Kezar Life Sciences announced that the mid-stage test of zetomipzomib in lupus nephritis had been placed ...

The findings, published in Immunity, could lead to new treatments targeting IL-1β to better manage inflammation in patients who don't respond well to existing therapies. Lupus is a chronic ...

Kezar (KZR) is discontinuing development of its drug zetomipzomib for the treatment of lupus nephritis so it can focus on ...

Kezar Life Sciences announced the termination of Phase 2b PALIZADE clinical trial of zetomipzomib, an investigational therapy ...